Amicus Therapeutics (NASDAQ:FOLD) Cut to “Hold” at StockNews.com

StockNews.com downgraded shares of Amicus Therapeutics (NASDAQ:FOLD) from a buy rating to a hold rating in a research report released on Thursday morning.

Several other equities research analysts also recently issued reports on FOLD. JPMorgan Chase & Co. upped their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Morgan Stanley reiterated an “equal weight” rating and set a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Monday, January 13th. Cantor Fitzgerald reiterated an “overweight” rating and set a $21.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Finally, Guggenheim upped their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $16.75.

Amicus Therapeutics Stock Up 1.3 %

Shares of FOLD opened at $9.19 on Thursday. The firm has a 50 day simple moving average of $9.56 and a two-hundred day simple moving average of $10.41. Amicus Therapeutics has a one year low of $8.78 and a one year high of $14.02. The company has a market cap of $2.82 billion, a P/E ratio of -51.06, a P/E/G ratio of 1.51 and a beta of 0.61. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42.

Insider Buying and Selling at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total transaction of $75,150.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $8,884,273.08. This represents a 0.84 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. OLD Second National Bank of Aurora purchased a new position in shares of Amicus Therapeutics during the 3rd quarter valued at $26,000. Hazlett Burt & Watson Inc. lifted its position in shares of Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 1,569 shares during the last quarter. Virtus Fund Advisers LLC purchased a new position in shares of Amicus Therapeutics during the 4th quarter valued at $29,000. Blue Trust Inc. lifted its position in shares of Amicus Therapeutics by 1,705.4% during the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,831 shares during the last quarter. Finally, Arcadia Investment Management Corp MI purchased a new position in shares of Amicus Therapeutics during the 3rd quarter valued at $32,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.